Editas Medicine Inc Stock Price, News & Analysis

Editas Medicine, Inc. (Nasdaq: EDIT) announced significant advancements in its clinical trials, including the second patient dosed in the Phase 1/2 RUBY trial for sickle cell disease, with preliminary clinical data expected by year-end 2022. The company also completed cell editing for the first patient in the EDITHAL trial for transfusion-dependent beta thalassemia and will provide a clinical update on the BRILLIANCE trial for EDIT-101 this month. Financially, Editas reported a net loss of $55.7 million for Q3 2022, up from $39.1 million in Q3 2021, with cash reserves of $478.5 million.

Editas Medicine, a clinical-stage genome editing company, will host a conference call on November 2, 2022, at 8:00 a.m. ET to discuss its third-quarter results. U.S. callers can dial 877-407-0989, while international participants can call 201-389-0921. The call will also be available via webcast on the company's website, with a replay accessible after the call. Editas Medicine specializes in developing transformative genomic medicines utilizing CRISPR technology.

Editas Medicine reported promising preclinical results for its experimental medicine EDIT-103, aimed at treating rhodopsin-associated autosomal dominant retinitis pigmentosa (RHO-adRP). The study, presented at the European Society of Gene and Cell Therapy meeting, showcased nearly 100% gene editing in non-human primates with more than 30% of replacement protein levels achieved. This CRISPR/Cas9-based therapy demonstrated effective knockout and replacement of the defective RHO gene with indications of preserved photoreceptor function, advancing towards IND-enabling studies.

Editas Medicine (Nasdaq: EDIT), a leader in genome editing, announced its participation in several upcoming investor conferences. The events include the 2022 Wells Fargo Healthcare Conference on September 7, with a 1:55 p.m. ET fireside chat in Everett, MA; the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, at 10:30 a.m. ET in New York, NY; and the Baird 2022 Global Healthcare Conference on September 13 in New York, NY. The chats will be webcast live and archived for 30 days on the company’s website.

Editas Medicine announced key developments, including the successful engraftment of the first patient treated with EDIT-301 for sickle cell disease and the removal of the FDA's partial clinical hold on the RUBY trial. The company appointed Baisong Mei, M.D., Ph.D., as Chief Medical Officer to strengthen its leadership team. Financially, Editas reported a net loss of $53.5 million for Q2 2022, with cash reserves of $527.6 million, sufficient to fund operations through 2024. EDIT-301 received FDA Orphan Drug Designation for transfusion-dependent beta thalassemia, and collaborations for cancer therapies were announced with Immatics and Bristol Myers Squibb.

Editas Medicine has successfully dosed and achieved neutrophil and platelet engraftment in the first patient in the Phase 1/2 RUBY trial of EDIT-301 for severe sickle cell disease. This marks the first clinical application of the AsCas12a enzyme for human gene editing. The FDA has lifted a partial hold on the trial, allowing the inclusion of efficacy data for future marketing applications. Additional patients are being enrolled across multiple U.S. and Canadian sites, with top-line clinical results expected by year-end 2022.

Editas Medicine (Nasdaq: EDIT) will host a conference call on August 3, 2022, at 8:00 a.m. ET to discuss its Q2 2022 financial results and corporate updates. U.S. callers can join by dialing 1-877-407-0989, while international callers should use +1-201-389-0921. The call will be accessible via a webcast on Editas Medicine's website, with a replay available one hour post-call. Editas focuses on genome editing with CRISPR technology, aiming to develop treatments for serious diseases.

Editas Medicine, Inc. (Nasdaq: EDIT) has granted an inducement stock option award to its newly appointed Chief Medical Officer, Dr. Baisong Mei. This option allows Dr. Mei to purchase up to 171,602 shares at a price of $14.99 each, reflecting the closing price on the grant date. The option vests over four years, with 25% vesting after the first year and the remainder monthly, contingent on Dr. Mei's continued service. Editas focuses on CRISPR/Cas9 and Cas12a technologies to develop genomic treatments for serious diseases.

Editas Medicine announced the appointment of Baisong Mei, M.D., Ph.D., as Senior Vice President and Chief Medical Officer. Dr. Mei will spearhead clinical research and drug development across various therapeutic areas, including hematology, oncology, and ophthalmology. With over 20 years of experience, he has a strong record in advancing innovative medicines through clinical development and regulatory approval. His leadership is expected to bolster Editas's pipeline and accelerate the delivery of transformative genomic medicines to patients.